Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL275571 | 0.76 | KDM4E (0.42) | ADRA2AADRA2BADRA2CADRA1APRKCZ | |
| SCHEMBL20873066 | 0.75 | PRKCZ (0.64) | ADRA2AADRA2BADRA2CADRA1APRKCZ | |
| SCHEMBL277591 | 0.74 | KDM4E (0.41) | ADRA2AADRA2BADRA2CADRA1AKDM4E | |
| SCHEMBL276517 | 0.73 | CYP3A4 (0.59) | PRKCZALDH1A1PRKCIKDM4ECYP3A4 | |
| SCHEMBL422347 | 0.71 | CYP2A6 (0.52) | ADRA2AADRA2BADRA2CADRA1APRKCZ | |
| SCHEMBL1325881 | 0.71 | CYP3A4 (0.57) | ADRA2AADRA2BADRA2CADRA1APRKCZ | |
| SCHEMBL197273 | 0.71 | CYP2A6 (0.52) | ADRA2AADRA2BADRA2CADRA1APRKCZ | |
| SCHEMBL111247 | 0.71 | PRKCZ (0.46) | ADRA2AADRA2BADRA2CADRA1APRKCZ | |
| SCHEMBL18805059 | 0.71 | CYP11B2 (0.47) | ADRA2AADRA2BADRA2CADRA1APRKCZ | |
| SCHEMBL1772312 | 0.71 | PRKCZ (0.46) | ADRA2AADRA2BADRA2CADRA1APRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115594631-A | Rosemastat key intermediate and preparation method of Rosemastat intermediate | 安徽省庆云医药股份有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| EP-3444238-B1 | PROCESS FOR PREPARING DIFLUOROMETHYLENE COMPOUNDS | SATO PHARMA (JP) | 2021-12-08 | — | — | EP | disclosed |
| EP-3444238-A2 | PROCESS FOR PREPARING DIFLUOROMETHYLENE COMPOUNDS | Sato Pharmaceutical Co., Ltd. (JP) | 2019-02-20 | — | — | EP | disclosed |
| EP-2878594-B1 | DIFLUOROMETHYLENE COMPOUND | SATO PHARMA (JP) | 2018-11-28 | — | — | EP | disclosed |
| US-9650380-B2 | Difluoromethylene compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2017-05-16 | — | — | US | disclosed |
| US-20170044158-A1 | DIFLUOROMETHYLENE COMPOUND | SATO PHARMACEUTICAL CO., LTD. (JP) | 2017-02-16 | — | — | US | disclosed |
| US-9512119-B2 | Difluoromethylene compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2016-12-06 | — | — | US | disclosed |
| US-9359350-B2 | Ring-fused compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-07 | — | — | US | disclosed |
| US-9115341-B2 | Method for expanding hematopoietic stem cells using heterocyclic compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-08-25 | — | — | US | disclosed |
| US-20150203490-A1 | RING-FUSED COMPOUND | SATO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| CN-1798739-A | 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators | NISSAN CHEMICAL IND LTD (JP) | 2006-07-05 | — | — | CN | disclosed |
| WO-2006062240-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2006-06-15 | — | — | WO | disclosed |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1636192-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004108683-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
| EP-1385833-A1 | TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | Amgen Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002083654-A1 | TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AMGEN INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NR2C2, ROR1, NR0B2 | ADRA2A 1025/4885ADRA2B 942/4885ADRA2C 1091/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | ADRA2A 746/4885ADRA2B 396/4885ADRA2C 478/4885 |
| US-20170044158-A1 | DIFLUOROMETHYLENE COMPOUND | XDH, URB2, MNAT1 | ADRA2A 2538/4885ADRA2B 3278/4885ADRA2C 3456/4885 |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | ADRA2A 82/4885ADRA2B 94/4885ADRA2C 86/4885 |
| US-20150203490-A1 | RING-FUSED COMPOUND | URB2, RCOR1, RCC2 | ADRA2A 596/4885ADRA2B 720/4885ADRA2C 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.